Eisai Submits Leqembi SBLA For IV Maintenance Dosing In Early Alzheimer's Disease
1/4 02:49
(RTTNews) - Eisai submitted to the U.S. Food and Drug Administration a Supplemental Biologics License Application or sBLA for monthly lecanemab-irmb (U.S. brand name: Leqembi) intravenous or IV maintenance dosing, Eisai Co., Ltd. and Biogen Inc. (BIIB) said in a statement....